Lemaitre Vascular price to free cash flow LMAT

Market value divided by free cash flow over the last twelve months, since 2012.

Today, Oct 23, 2026: 26.2×
10-year median: 41.3×
Against its 10-year history: 8th; percentile: 0 is its lowest day, 100 its highest
10-year range: 4.8× to 83.4×
Peer median: 23.8×

Lemaitre Vascular's price to free cash flow is 26.2× as of Oct 23, 2026.

That is below its ten-year median of 41.3×, lower than on 92% of days in the last ten years.

Over that time it ranged from 4.8× in Mar 2020 to 83.4× in Jun 2023.

The median for 10 medical instruments and supplies stocks of a similar size is 23.8×.

Price to free cash flow over time

median 41.3×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	26.2×	24.4×	35.1×
2025	28.7×	28.4×	66.8×
2024	62.3×	47.9×	72.5×
2023	55.3×	42.1×	83.4×
2022	42.6×	23.1×	43.6×
2021	28.3×	26.4×	45.3×
2020	35.7×	4.8×	57.1×
2019	6.3×	6.0×	61.2×
2018	28.2×	26.8×	41.0×
2017	n/m a value too high to mean anything
2016	33.7×	23.7×	33.7×
2015	37.9×	29.4×	45.9×
2014	42.1×	39.1×	84.4×
2013	78.0×	26.3×	98.9×
2012	34.2×	18.1×	37.9×

Against its peers

Companies in Medical - Instruments & Supplies nearest Lemaitre Vascular's size, closest first, today.

Company	Price to free cash flow
LMATLemaitre Vascular	26.2×
INSPInspire Medical Systems	17.6×
UFPTUFP Technologies	n/m
EYENational Vision	30.1×
CDRECadre	16.4×
BVSBioventus	13.3×
ATRCAtriCure	56.5×
WRBYWarby Parker	147×
STAAStaar Surgical	n/m
IRMDIradimed	43.7×
NVSTEnvista	15.3×
Peer median	23.8×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Lemaitre Vascular

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.